Trial · NCT03048019
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
NCT03048019, Terminated, Inova Health Care Services; results first posted 2023-12-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention. Trials, record NCT03048019. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03048019
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
- NCT number
- NCT03048019
- Status
- Terminated
- Enrollment
- 10 participants, actual
- Lead sponsor
- Inova Health Care Services
- Conditions
- Non-ST Elevation Myocardial Infarction (NSTEMI)
- Interventions
- Tirofiban, Cangrelor
- First posted
- 2017-02-09
- Last updated
- 2023-12-11
- Results first posted
- 2023-12-11
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Thrombin Receptor Activator Peptide (TRAP) Induced Platelet Aggregation (%) | 30 minutes post-start of the infusion | Assessment of platelet aggregation (%) in response to 10uM thrombin receptor activator peptide. Normal reference range is 60-100% aggregation. |
| Secondary | Adenosine Diphosphate (ADP) Induced Platelet Aggregation (%) | 30 minutes post-start of the infusion | Assessment of platelet aggregation (%) in response to 20uM ADP at baseline and serially following tirofiban or cangrelor infusion. Normal reference range is 60-100% aggregation. |
| Secondary | Thrombin Induced Platelet-fibrin Clot Strength (mm) | 30 minutes post-start of the infusion | Assessment of thrombin induced platelet-fibrin clot strength (mm) by thromboelastography (TEG6S). Normal reference range is 55-68 mm |
| Secondary | Shear-induced Thrombus Formation (AUC) | 30 minutes after the end of the infusion. | Real time evaluation of shear-induced thrombus formation using novel RUO T-TAS plus system. AUC is calculated as time to reach 60 kPa |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Thrombin Receptor Activator Peptide (TRAP) Induced Platelet Aggregation (%) | 30 minutes post-start of the infusion | % aggregation | MEAN | |
| SECONDARY | Adenosine Diphosphate (ADP) Induced Platelet Aggregation (%) | 30 minutes post-start of the infusion | % aggregation | MEAN | |
| SECONDARY | Thrombin Induced Platelet-fibrin Clot Strength (mm) | 30 minutes post-start of the infusion | mm | MEAN | |
| SECONDARY | Shear-induced Thrombus Formation (AUC) | 30 minutes after the end of the infusion. | kPa*min | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Thrombin Receptor Activator Peptide (TRAP) Induced Platelet Aggregation (%) | Tirofiban Therapy | 42.5 | Standard Deviation 10.2 | % aggregation | |
| Thrombin Receptor Activator Peptide (TRAP) Induced Platelet Aggregation (%) | Cangrelor Therapy | 71.2 | Standard Deviation 6.9 | % aggregation | |
| Adenosine Diphosphate (ADP) Induced Platelet Aggregation (%) | Tirofiban Therapy | 3.3 | Standard Deviation 3.1 | % aggregation | |
| Adenosine Diphosphate (ADP) Induced Platelet Aggregation (%) | Cangrelor Therapy | 39.4 | Standard Deviation 13.1 | % aggregation | |
| Thrombin Induced Platelet-fibrin Clot Strength (mm) | Tirofiban Therapy | 63.9 | Standard Deviation 2.7 | mm | |
| Thrombin Induced Platelet-fibrin Clot Strength (mm) | Cangrelor Therapy | 62.3 | Standard Deviation 3.6 | mm | |
| Shear-induced Thrombus Formation (AUC) | Tirofiban Therapy | 14.1 | Standard Deviation 13.7 | kPa*min | |
| Shear-induced Thrombus Formation (AUC) | Cangrelor Therapy | 1004 | Standard Deviation 884 | kPa*min |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tirofiban Therapy | 5 | |
| Overall Study | STARTED | Cangrelor Therapy | 5 | |
| Overall Study | COMPLETED | Tirofiban Therapy | 4 | |
| Overall Study | COMPLETED | Cangrelor Therapy | 5 | |
| Overall Study | NOT COMPLETED | Tirofiban Therapy | 1 | |
| Overall Study | NOT COMPLETED | Cangrelor Therapy | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Paresthesia | Nervous system disorders | Tirofiban Therapy | 0 | 5 | 0 |
| other | Paresthesia | Nervous system disorders | Cangrelor Therapy | 1 | 5 | 1 |
| serious | Bleeding | Surgical and medical procedures | Tirofiban Therapy | 1 | 5 | 1 |
| serious | Bleeding | Surgical and medical procedures | Cangrelor Therapy | 0 | 5 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tirofiban Therapy | 0 | 5 |
| Total, all-cause mortality | Cangrelor Therapy | 0 | 5 |
| Total, other adverse events | Tirofiban Therapy | 0 | 5 |
| Total, other adverse events | Cangrelor Therapy | 1 | 5 |
| Total, serious adverse events | Tirofiban Therapy | 1 | 5 |
| Total, serious adverse events | Cangrelor Therapy | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Tirofiban Therapy vs Cangrelor Therapy: deaths from any cause | Trial comparisons |
| Tirofiban Therapy vs Cangrelor Therapy: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03048019
GET https://conductscience.org/api/trials/v1/NCT03048019/registered